Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
A deregulation of NAD+ levels is associated with signs of aging, metabolic diseases, neurodegeneration, and cancer
HIPAA-secure | Only pay if prescribed *Displayed price reflects a 3-month plan
It functions as a dual GLP-1 and GIP receptor agonist , offering: Enhanced insulin secretion Delayed gastric emptying Appetite suppression Improved glycemic control Tirzepatide demonstrated impressive clinical outcomes in the SURMOUNT and SURPASS trials, with average weight loss of 15-22.5% and substantial A1C reductions
Shahmiri M, Enciso M, Adda CG, Smith BJ, Perugini MA, Mechler A
US$ 23.10
US$ 21.84
US$ 20.33
US$ 21.33
US$ 29.50
